GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alnylam Pharmaceuticals, Inc. (ALNY) [hlAlert]

Rating:
Buy ALNY
up 371.46 %

Alnylam Pharmaceuticals, Inc. (ALNY) rated Buy with price target $28 by Jefferies & Co

Posted on: Wednesday,  Jun 10, 2009  8:25 AM ET by Jefferies & Co

Jefferies & Co rated Buy Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 06/10/2009, when the stock price was $22.25.
Since then, Alnylam Pharmaceuticals, Inc. has gained 371.46% as of 01/22/2016's recent price of $104.90.
If you would have followed this Jefferies & Co's recommendation on ALNY, you would have gained 371.46% of your investment in 2417 days.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Our focus on growing and mid-sized companies enables us to identify unique investment ideas, which can make the difference in a tough market. Jefferies' research effort covers U.S. & International equity, high yield, convertibles, investment grade fixed income and post-reorganization securities, as well as special situations and quantitative research. The more than 120-person team of research professionals covers over 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes and dig deeper to provide in-depth, thought provoking, objective research. Our analysts use a variety of quantitative and qualitative tools, integrating field analysis, proprietary channel checks and ongoing dialogue with the managements of the companies they cover. We utilize the latest technologies to deliver a research product that is timely, differentiated, and tailored to each customer's needs. Regular client access to companies and their management teams is provided through a wide variety of Jefferies hosted industry conferences, company management meetings and on-site tours.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/10/2009 8:25 AM Buy
None
22.25 28.00
as of 12/31/2009
1 Week down  -41.04 %
1 Month down  -36.94 %
3 Months down  -53.26 %
1 YTD down  -52.35 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy